MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, up 26% year-over-year, plus more than $1.0 million in SPL Program-related revenue including a $1.0 million partner milestone. The company raised full-year 2026 guidance to roughly $34 million in total revenue, up from the prior $30-32 million range, with core business revenue guidance lifted to ~$28 million. Management attributed the beat to accelerated instrument purchasing by a large customer originally expected in Q4, and now supports two pivotal trials with potential approvals as early as 2027.
Key figures
- Revenue
- $8.1 million
- Guidance
- FY2026 total revenue ~$34M (raised from $30M-$32M); core business ~$28M (from $25M-$27M); SPL Program-related ~$6M (from ~$5M)
- Revenue Yoy
- 26%
- Fy spl revenue
- $6 million
- Fy core revenue
- $28 million
- Q3 milestone revenue
- $1.0 million
- Second half yoy growth
- 15%
- Spl program q3 revenue
- $1.0 million+
- Core business q3 revenue
- 8100000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.